Work

Supplementary Figure 2 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure 2: Viral replication is integral to RUX/C134 anti-tumor effect.

DOI: 10.1158/2326-6066.22539610

Authors: Mohammed G. Ghonime, Kevin A. Cassady

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362618909

Cites:

Cited by:

Related to: 10